Enforcement teams across Maharashtra have intensified ground operations to weed out counterfeit, substandard, and unlicensed medical supplies from circulation. Official operational records released on October 14 show that 4,256 inspections were executed across drug manufacturing units and distribution networks between June and September 2026. During this four-month enforcement window, regulatory authorities seized or prohibited medical inventory valued at 19.11 crore rupees. Legal proceedings escalated as well, resulting in the registration of 33 FIRs and the arrest of 14 individuals linked to fraudulent distribution channels. Compared to the preceding period of April and May 2026, when only 467 total inspections were conducted, average monthly inspections surged approximately 4.6 times during the June to September drive.
Over 1400 Notices and Stringent Licensing Penalties
Audits across pharmaceutical units led to strict disciplinary steps against non-compliant businesses. Regulatory actions touched 148 manufacturing facilities and 996 retail and wholesale drug outlets between June and September. In total, 1,402 regulatory notices were served to defaulting businesses. Where egregious violations came to light, regulators cancelled 288 establishment licences outright and suspended another 856 licences. Factory-level scrutiny saw a sharp jump: inspectors visited 965 manufacturing units during the four months, up from just 120 inspections in April and May. Simultaneously, store and pharmacy inspections climbed from 347 to 3,291 visits.
Cracking Down on Unlicensed Batches and Spurious Cosmetics
The enforcement exercise revealed diverse violations across the supply pipeline. Between June and September, authorities tackled 43 distinct cases concerning unlicensed warehousing and commercial sale of medicinal products. Scrutiny under the Drugs and Magic Remedies Objectionable Advertisements Act, 1954 led to 31 cases against misleading claims and illegal medical promotions. The crackdown uncovered 14 cases involving spurious medicines and counterfeit cosmetics, alongside 10 cases of misbranded cosmetic lines. Enforcement officers booked 9 cases under NDPS regulations for illicit narcotics abuse. Furthermore, inspectors flagged 3 violations involving medical devices, 3 instances of deceptive brand-name imitation designed to mislead consumers, and 2 breaches of mandatory packaging labelling rules.
Search and Seizure Values Leap Eightfold
A statistical comparison with early 2026 demonstrates the scale of the expanded surveillance. In April and May, authorities executed 8 search and seizure missions, intercepting contraband supplies worth around 1.12 crore rupees. Over the subsequent four months, the count of targeted search operations climbed to 115, while the value of seized or prohibited stock jumped to nearly 19.11 crore rupees. Evaluated on a monthly average baseline, the value of intercepted supplies grew roughly 8.5 times. In addition, the rate of lodging formal criminal complaints expanded 8.2-fold, and search-and-seizure drives increased by about 7.2 times.
Zero Tolerance on Public Safety
Maharashtra FDA Commissioner Tukaram Munde affirmed that protecting public health remains the administration's primary obligation. Munde stated that the sharp rise in enforcement actions over the last four months reflects institutional vigilance. He indicated that comprehensive statewide inspections would continue without pause to block substandard, spurious, and unlicensed drugs from entering the open market, ensuring strict legal consequences for perpetrators.
